Europe
United Kingdom
Europe
United Kingdom

The 'go to' European specialist pharma company

Therapy areas

Our core therapy areas of focus are gastroenterology, hepatology, critical and supportive care.

 
Gastroenterology
We have a long standing expertise in gastroenterology – from macrogol-based laxatives to bowel preparation.

20 per cent of adults aged over 65 are constipated.1

We are also exploring new treatment options to treat faecal incontinence, to address the unmet medical needs in this debilitating disease which may severely restrict patients’ activities of daily living.

In major European countries, around 5 per cent of all adult men and women will suffer from faecal incontinence.2
 
Hepatology

We are committed to the management of hepatic encephalopathy, a common and serious neuropsychiatric syndrome associated with cirrhosis.3-5

 

Hepatic encephalopathy exerts a formidable burden on the healthcare system, patients and their families.7

 

Episodes of overt hepatic encephalopathy frequently result in hospitalisation3 and may be predictive of reduced survival.5
 

 

 
Critical & Supportive Care

We are committed to help patients with some of the major cancer-related symptoms such as nausea, vomiting, pain, constipation, xerostomia and malnutrition.

 

Constipation occurs in approximately 30-50 per cent of cancer patients.9-11

 

Nausea and/or vomiting are experienced by most cancer patients. Despite significant antiemetic advances, almost 50 per cent of treated cancer patients still experience nausea and/or vomiting.7

 

Malnutrition, frequently associated with weight loss, is an independent factor of quality of life deterioration.13

 

 

 

 

  1. Bosshard W, Dreher R, Schnegg J et al. ‘The treatment of chronic constipation in elderly people. An update’, Drugs Aging, 2004; 21 (14): 911-30;
  2. Michael Probst et al. Dtsch Arztebl Int 2010; 107(34–35): 596–601
  3. Poordad, F., Aliment Pharmacol Ther, 2006; 25(Suppl 1): 3-9.
  4. Cordoba, J., J Hepatol, 2011; 54(5): 1030-40.
  5. Prakash, R., & Mullen, K.D., Nat Rev Gastroenterol Hepatol, 2010; 7(9): 515-25.
  6. Ortiz M, et al. J Hepatol. 2005;42(Suppl 1):S45–53
  7. Bass NM. Aliment Pharmacol Ther. 2007;25(Suppl 1):23–31
  8. Amodio P, et al. J Hepatol. 2001;35:37–45
  9. Woolery M. Putting Evidence Into Practice®: Evidence-Based Interventions for the Prevention and Management of Constipation in Patients With Cancer Clin J Oncol Nurs.  2008 ; 12 : 317-337.
  10. Droney J. Constipation in cancer patients on morphine Support Care Cancer 2008 ; 16 : 453-459.
  11. Laugsand EA et al. Inadequate symptom control in advanced cancer patients across Europe. Support Care Cancer 2011 ; 19 : 2005-201.
  12. Warr D. Chemotherapy- and cancer-related nausea and vomiting. Current oncology. 2008 ; 15 : S4-S9
  13. Nourrissat A et al. Relationship between nutritional status and quality of life in patients with cancer. Eur J Cancer 2008 ; 44 : 1238-1242